Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III StudyLarry W. Kwak, Christian Buske, Junji Suzumiya et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 14
Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 MonthsChristian Buske, Keum Young Ahn, Larry W. Kwak et al.|Blood|2019Cited by 3